Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: tryptophan hydroxylase inhibitors - Enzyvant

Next Previous
Drug Profile

Research programme: tryptophan hydroxylase inhibitors - Enzyvant

Alternative Names: TPH1 inhibitors

Latest Information Update: 09 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karos Pharmaceuticals
  • Developer Enzyvant
  • Class Small molecules
  • Mechanism of Action Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant carcinoid syndrome

Most Recent Events

  • 06 Dec 2022 Altavant Sciences has been merged with Enzyvant to form Enzyvant
  • 28 May 2020 No recent reports of development identified for preclinical development in malignant carcinoid syndrome in USA
  • 06 Jan 2020 Sumitomo Dainippon Pharma acquired all rights of five companies namely Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences from Riovant and transferred it to Sumitovant Biopharma (a subsidiary of Sumitomo Dainippon Pharma)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top